|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DOCK3 |
Gene summary for DOCK3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DOCK3 | Gene ID | 1795 |
| Gene name | dedicator of cytokinesis 3 | |
| Gene Alias | MOCA | |
| Cytomap | 3p21.2 | |
| Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | Q8IZD9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1795 | DOCK3 | RNA-P17T-P17T-8 | Human | Lung | IAC | 1.55e-04 | 5.81e-01 | 0.3329 |
| 1795 | DOCK3 | RNA-P3T-P3T-4 | Human | Lung | IAC | 2.14e-03 | 3.49e-01 | 0.1859 |
| 1795 | DOCK3 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 4.21e-10 | 8.16e-01 | -0.0961 |
| 1795 | DOCK3 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 8.10e-12 | 8.04e-01 | -0.0876 |
| 1795 | DOCK3 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 7.13e-10 | 8.23e-01 | -0.0822 |
| 1795 | DOCK3 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 1.02e-08 | 6.30e-01 | -0.0809 |
| 1795 | DOCK3 | male-WTA | Human | Thyroid | PTC | 3.97e-19 | 1.69e-01 | 0.1037 |
| 1795 | DOCK3 | PTC01 | Human | Thyroid | PTC | 7.42e-12 | 7.18e-02 | 0.1899 |
| 1795 | DOCK3 | PTC03 | Human | Thyroid | PTC | 1.05e-09 | 3.40e-01 | 0.1784 |
| 1795 | DOCK3 | PTC04 | Human | Thyroid | PTC | 4.05e-10 | 1.53e-01 | 0.1927 |
| 1795 | DOCK3 | PTC05 | Human | Thyroid | PTC | 3.40e-16 | 5.12e-01 | 0.2065 |
| 1795 | DOCK3 | PTC06 | Human | Thyroid | PTC | 7.47e-28 | 7.49e-01 | 0.2057 |
| 1795 | DOCK3 | PTC07 | Human | Thyroid | PTC | 8.20e-16 | 2.57e-01 | 0.2044 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00510565 | Lung | IAC | regulation of small GTPase mediated signal transduction | 70/2061 | 302/18723 | 9.44e-10 | 1.87e-07 | 70 |
| GO:00458607 | Lung | IAC | positive regulation of protein kinase activity | 72/2061 | 386/18723 | 4.89e-06 | 1.96e-04 | 72 |
| GO:00336748 | Lung | IAC | positive regulation of kinase activity | 83/2061 | 467/18723 | 6.76e-06 | 2.45e-04 | 83 |
| GO:005105611 | Lung | AIS | regulation of small GTPase mediated signal transduction | 66/1849 | 302/18723 | 4.26e-10 | 9.53e-08 | 66 |
| GO:003367412 | Lung | AIS | positive regulation of kinase activity | 77/1849 | 467/18723 | 4.67e-06 | 2.31e-04 | 77 |
| GO:004586012 | Lung | AIS | positive regulation of protein kinase activity | 65/1849 | 386/18723 | 1.27e-05 | 4.78e-04 | 65 |
| GO:0018212 | Lung | AIS | peptidyl-tyrosine modification | 56/1849 | 378/18723 | 1.35e-03 | 1.68e-02 | 56 |
| GO:0018108 | Lung | AIS | peptidyl-tyrosine phosphorylation | 55/1849 | 375/18723 | 1.87e-03 | 2.08e-02 | 55 |
| GO:0045860111 | Thyroid | PTC | positive regulation of protein kinase activity | 176/5968 | 386/18723 | 8.89e-09 | 2.17e-07 | 176 |
| GO:0033674111 | Thyroid | PTC | positive regulation of kinase activity | 201/5968 | 467/18723 | 1.95e-07 | 3.54e-06 | 201 |
| GO:005105617 | Thyroid | PTC | regulation of small GTPase mediated signal transduction | 132/5968 | 302/18723 | 9.26e-06 | 1.04e-04 | 132 |
| GO:00610974 | Thyroid | PTC | regulation of protein tyrosine kinase activity | 45/5968 | 90/18723 | 2.57e-04 | 1.84e-03 | 45 |
| GO:00182126 | Thyroid | PTC | peptidyl-tyrosine modification | 142/5968 | 378/18723 | 1.02e-02 | 4.14e-02 | 142 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DOCK3 | SNV | Missense_Mutation | novel | c.3856N>C | p.Glu1286Gln | p.E1286Q | Q8IZD9 | protein_coding | tolerated(0.16) | probably_damaging(0.999) | TCGA-A2-A4RW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| DOCK3 | SNV | Missense_Mutation | c.3002N>C | p.Arg1001Thr | p.R1001T | Q8IZD9 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DOCK3 | SNV | Missense_Mutation | rs768565725 | c.809N>A | p.Arg270Gln | p.R270Q | Q8IZD9 | protein_coding | tolerated(0.06) | probably_damaging(0.98) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DOCK3 | SNV | Missense_Mutation | novel | c.1560N>T | p.Lys520Asn | p.K520N | Q8IZD9 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DOCK3 | SNV | Missense_Mutation | novel | c.4062N>A | p.Phe1354Leu | p.F1354L | Q8IZD9 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DOCK3 | SNV | Missense_Mutation | novel | c.2614N>C | p.Glu872Gln | p.E872Q | Q8IZD9 | protein_coding | deleterious(0.01) | probably_damaging(0.954) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| DOCK3 | SNV | Missense_Mutation | c.1351C>A | p.Leu451Ile | p.L451I | Q8IZD9 | protein_coding | deleterious(0.04) | possibly_damaging(0.557) | TCGA-D8-A1XF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
| DOCK3 | SNV | Missense_Mutation | c.4332N>A | p.Ser1444Arg | p.S1444R | Q8IZD9 | protein_coding | tolerated(0.2) | probably_damaging(1) | TCGA-E2-A1B4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD | |
| DOCK3 | SNV | Missense_Mutation | c.1304N>C | p.Arg435Thr | p.R435T | Q8IZD9 | protein_coding | deleterious(0) | possibly_damaging(0.9) | TCGA-E9-A244-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| DOCK3 | SNV | Missense_Mutation | novel | c.5075C>G | p.Ala1692Gly | p.A1692G | Q8IZD9 | protein_coding | tolerated_low_confidence(0.52) | benign(0.027) | TCGA-E9-A2JS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |